APA (7th ed.) Citation

Falcitano, L., Calizzano, F., Mattioli, P., Kiersnowski, O. C., Avanzino, L., Girtler, N. G., . . . Arnaldi, D. (2026). MRI susceptibility map weighted imaging (SMWI) as a neurodegeneration biomarker in the prodromal to overt alpha-synucleinopathy continuum. Journal of Parkinson's Disease, 16(1), 61. https://doi.org/10.1177/1877718X251387027

Chicago Style (17th ed.) Citation

Falcitano, Laura, et al. "MRI Susceptibility Map Weighted Imaging (SMWI) as a Neurodegeneration Biomarker in the Prodromal to Overt Alpha-synucleinopathy Continuum." Journal of Parkinson's Disease 16, no. 1 (2026): 61. https://doi.org/10.1177/1877718X251387027.

MLA (9th ed.) Citation

Falcitano, Laura, et al. "MRI Susceptibility Map Weighted Imaging (SMWI) as a Neurodegeneration Biomarker in the Prodromal to Overt Alpha-synucleinopathy Continuum." Journal of Parkinson's Disease, vol. 16, no. 1, 2026, p. 61, https://doi.org/10.1177/1877718X251387027.